Evidence map›Paper›PMID 38089084›Full record

ArticleCancer innovation2022

Evaluation of quality of clinical management of neuroendocrine tumors.

Hannah Bloemen, Kristien Kneepkens, Karen Deraedt, Anna Ivanova, Gregory Sergeant, Jeroen Mebis, Kurt Van der Speeten

Open access · diamondAbstract read
In one paragraph

Article in Cancer innovation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hannah BloemenDepartment of Medicine, Faculty of Medicine and Life Sciences (LCRC) Hasselt University Diepenbeek Belgium.ORCID 0000-0002-4326-8854
Kristien KneepkensDepartment of Medicine, Faculty of Medicine and Life Sciences (LCRC) Hasselt University Diepenbeek Belgium.
Karen DeraedtDepartment of Pathology and Department Future Health Ziekenhuis Oost-Limburg Genk Belgium.
Anna IvanovaDepartment of Medicine, Faculty of Medicine and Life Sciences (LCRC) Hasselt University Diepenbeek Belgium.
Gregory SergeantDepartment of Medicine, Faculty of Medicine and Life Sciences (LCRC) Hasselt University Diepenbeek Belgium.
Jeroen MebisDepartment of Medicine, Faculty of Medicine and Life Sciences (LCRC) Hasselt University Diepenbeek Belgium.
Kurt Van der SpeetenDepartment of Medicine, Faculty of Medicine and Life Sciences (LCRC) Hasselt University Diepenbeek Belgium.
Hasselt University · BEJessa Hospital · BEZiekenhuis Oost-Limburg · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuroendocrine tumors (NETs) are a group of biologically and clinically heterogeneous neoplasms predominantly found in the gastrointestinal and bronchopulmonary tractus. Despite a rising incidence, implementation of evidence-based standardized care for this heterogenous group remains challenging. The European Neuroendocrine Tumor Society regularly reviews guidelines regarding diagnostic and treatment strategies for NETs. The aim of this study is to shed light on the care of patients with a NET in Belgian Limburg, to provide data as a basis for future studies and to check whether data and results are according to consensus guidelines and outcomes described in literature. Methods: Our study concerned a detailed observational data collection of two large Belgian hospitals (Jessa Hospital Hasselt and Hospital Oost-Limburg Genk) with special interest in patient profile, quality of pathology reports, use of diagnostic imaging, and overall survival. Data on 188 patients were assembled between January 2010 and December 2014 with follow-up until June 2016 (median follow-up: 33.6 months). Results: Fifty percent of patients were male. NETs were located mainly in the digestive tract (63.8%) and lung (20.2%). Appendiceal NETs were diagnosed at a significantly younger age than other tumors (41.3 vs. 64.0 years). Overall, a mean pathology report quality score of 3.0/5 was observed with the highest scores for small bowel NETs. Diagnostic and nuclear imaging was performed in 74.5% and 29.8% of cases, respectively. Seventy-four percent of the population survived until the end of the observation period with highest survival rates for appendiceal and small bowel NETs. Conclusion: Overall, epidemiological results were comparable with findings in the literature. Gastrointestinal NETs met most of the requirements of qualitative pathology reporting and diagnostic imaging as listed in the European Neuroendocrine Tumor Society consensus guidelines. However, consensus with regard to bronchopulmonary NETs is still scarce and remains an objective for future research. Moreover, discussing treatment strategies in specialized multidisciplinary tumor boards would facilitate regional care.

Indexed as

epidemiologyguidelinesKi67neuroendocrine tumorsoverall survivalpathology reportquality

Identifiers

PMID38089084
PMCPMC10686178
OpenAlexW4311623793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.